Aptamer Group Plc (APTA) Price & Analysis

Compare

11 Followers

APTA Stock Chart & Stats

0.80p

-0.01p(-2.86%)

At close: Jan 09 4:00 PM EST

0.80p

-0.01p(-2.86%)

Day’s Range― - ―

52-Week Range0.23p - 1.57p

Previous CloseN/A

Volume3.91M

Average Volume (3M)15.29M

Market Cap

£24.27M

Enterprise Value24.38M

Total Cash (Recent Filing)£1.06M

Total Debt (Recent Filing)£491.00K

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding2,696,978,300

10 Day Avg. Volume14,821,052

30 Day Avg. Volume15,285,032

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)5.32

Price to Sales (P/S)6.11

P/FCF Ratio-3.66

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Aptamer TechnologyAptamer Group's core platform—synthetic aptamers with specific binding properties—creates a durable scientific moat. Platform technologies support repeatable custom discovery projects, licensing and productization across diagnostics and therapeutics, sustaining revenue opportunities and partnering leverage over the medium term.

Diversified Commercial Revenue StreamsMultiple revenue channels (custom services, partnerships with upfront/milestone payments, and direct product sales) provide structural resiliency. Long-term collaborations and milestone-linked contracts can smooth cash timing, increase visibility and create recurring business that supports stability across 2–6 months and beyond.

Improved Leverage ManagementAn improved debt-to-equity profile reduces refinancing and solvency risk, giving management more financial flexibility to fund R&D, support partnerships or absorb short-term revenue variability. Lower leverage improves resilience versus peers when raising capital or negotiating collaborations over the medium term.

Bears Say

Severe Revenue DeclineA near-total revenue collapse signals lost commercial traction or lapsed major contracts, materially reducing scale economics. Over 2–6 months this impairs the firm's ability to cover fixed R&D and operating costs, heightens reliance on external financing, and undermines confidence in recovery absent new contract wins.

Negative Operating And Free Cash FlowPersistent negative operating and free cash flows deplete reserves and force reliance on new capital or dilutive financing. This constrains investment in platform development and commercialization, raises execution risk on partnerships, and creates structural funding pressure over the medium term if cash generation doesn't improve.

Ongoing Losses And Negative ReturnsNegative net/EBIT margins and a negative ROE indicate the company is not generating shareholder returns and is operating at a structural loss. This reduces internal funding capacity, makes external capital more expensive, and limits the firm's ability to scale operations or invest in new programs sustainably over coming months.

Aptamer Group Plc News

Aptamer Group hits key milestone in Metir pathogen detector collaboration

Aptamer Group Plc ( ($GB:APTA) ) has provided an announcement. Aptamer Group plc has completed Phase 1 of...

7d ago

Aptamer’s Optimer Tech Powers Twist Bioscience’s New TrueAmp NGS Library Prep Kit

Aptamer Group Plc ( ($GB:APTA) ) has shared an update. Twist Bioscience has launched its new TrueAmp Library...

13d ago

Aptamer Group Secures New Pharma Contracts and First Cash from Optimer Licensing

An announcement from Aptamer Group Plc ( ($GB:APTA) ) is now available. Aptamer Group has reported £190,000 of...

26d ago

Aptamer Group Reasserts Cash Runway to June 2027 Amid Media Speculation

Aptamer Group Plc ( ($GB:APTA) ) has issued an announcement. Aptamer Group plc issued a brief trading update...

2M ago

Aptamer Group lifts H1 revenue 27% as licensing push builds recurring income

Aptamer Group Plc ( ($GB:APTA) ) has shared an announcement. Aptamer Group reported a 27% year-on-year rise in...

2M ago

Aptamer Group Secures Second Enzyme-Modulation Licence with Alphazyme for Hot-Start PCR Optimer

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has signed a non-exclusive worldwide OEM...

2M ago

Aptamer Group Partners with Twist Bioscience for NGS Market Expansion

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group plc has entered into a non-exclusive...

2M ago

Aptamer Group PLC Reports Strong Commercial Momentum and Strategic Progress

Aptamer Group Plc ( ($GB:APTA) ) has shared an update. Aptamer Group PLC has reported significant commercial momentum...

3M ago

Aptamer Group Secures Key Contracts, Strengthening Commercial Momentum

An announcement from Aptamer Group Plc ( ($GB:APTA) ) is now available. Aptamer Group plc has announced significant...

3M ago

Aptamer Group Secures Major Contract with Top Pharmaceutical Partner

Aptamer Group Plc ( ($GB:APTA) ) has provided an update. Aptamer Group has secured a significant new contract...

4M ago

APTA FAQ

What was Aptamer Group Plc’s price range in the past 12 months?

Aptamer Group Plc lowest share price was 0.23p and its highest was 1.57p in the past 12 months.

What is Aptamer Group Plc’s market cap?

Aptamer Group Plc’s market cap is £24.27M.

When is Aptamer Group Plc’s upcoming earnings report date?

Aptamer Group Plc’s upcoming earnings report date is Mar 26, 2026 which is in 30 days.

How were Aptamer Group Plc’s earnings last quarter?

Aptamer Group Plc released its earnings results on Oct 14, 2025. The company reported -0.001p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001p.

Is Aptamer Group Plc overvalued?

According to Wall Street analysts Aptamer Group Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptamer Group Plc pay dividends?

Aptamer Group Plc does not currently pay dividends.

What is Aptamer Group Plc’s EPS estimate?

Aptamer Group Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptamer Group Plc have?

Aptamer Group Plc has 2,696,978,300 shares outstanding.

What happened to Aptamer Group Plc’s price movement after its last earnings report?

Aptamer Group Plc reported an EPS of -0.001p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.111%.

Which hedge fund is a major shareholder of Aptamer Group Plc?

Currently, no hedge funds are holding shares in GB:APTA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aptamer Group Plc

Aptamer Group Plc (APTA) is a biotechnology company that specializes in the development of novel aptamer-based technologies for various applications in diagnostics, therapeutics, and research. The company operates primarily in the life sciences sector, focusing on providing high-quality, synthetic aptamers—short, single-stranded oligonucleotides that can bind to specific target molecules. Aptamer Group's core products and services include the design and production of aptamers for use in pharmaceutical development, as well as tools for biomarker discovery and diagnostics.